282 related articles for article (PubMed ID: 22911820)
1. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
[TBL] [Abstract][Full Text] [Related]
2. Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells.
Lee II; Maniar K; Lydon JP; Kim JJ
Oncogene; 2016 Sep; 35(39):5191-201. PubMed ID: 26996671
[TBL] [Abstract][Full Text] [Related]
3. Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis.
Neubauer NL; Ward EC; Patel P; Lu Z; Lee I; Blok LJ; Hanifi-Moghaddam P; Schink J; Kim JJ
Horm Cancer; 2011 Jun; 2(3):170-81. PubMed ID: 21760855
[TBL] [Abstract][Full Text] [Related]
4. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.
Zhao YY; Tian Y; Zhang J; Xu F; Yang YP; Huang Y; Zhao HY; Zhang JW; Xue C; Lam MH; Yan L; Hu ZH; Dinglin XX; Zhang L
Drug Des Devel Ther; 2014; 8():1827-37. PubMed ID: 25336925
[TBL] [Abstract][Full Text] [Related]
5. Activated AKT pathway promotes establishment of endometriosis.
Kim TH; Yu Y; Luo L; Lydon JP; Jeong JW; Kim JJ
Endocrinology; 2014 May; 155(5):1921-30. PubMed ID: 24605828
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
[TBL] [Abstract][Full Text] [Related]
7. Increased AKT or MEK1/2 activity influences progesterone receptor levels and localization in endometriosis.
Eaton JL; Unno K; Caraveo M; Lu Z; Kim JJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1871-9. PubMed ID: 24064688
[TBL] [Abstract][Full Text] [Related]
8. CDC2 mediates progestin initiated endometrial stromal cell proliferation: a PR signaling to gene expression independently of its binding to chromatin.
Vallejo G; La Greca AD; Tarifa-Reischle IC; Mestre-Citrinovitz AC; Ballaré C; Beato M; Saragüeta P
PLoS One; 2014; 9(5):e97311. PubMed ID: 24859236
[TBL] [Abstract][Full Text] [Related]
9. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
Li Z; Yan S; Attayan N; Ramalingam S; Thiele CJ
Clin Cancer Res; 2012 Jul; 18(13):3603-15. PubMed ID: 22550167
[TBL] [Abstract][Full Text] [Related]
10. The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer.
Winder A; Unno K; Yu Y; Lurain J; Kim JJ
Cancer Biol Ther; 2017 Dec; 18(12):958-964. PubMed ID: 28112582
[TBL] [Abstract][Full Text] [Related]
11. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
[TBL] [Abstract][Full Text] [Related]
12. The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma.
Ward EC; Hoekstra AV; Blok LJ; Hanifi-Moghaddam P; Lurain JR; Singh DK; Buttin BM; Schink JC; Kim JJ
Endocrinology; 2008 Apr; 149(4):1942-50. PubMed ID: 18096667
[TBL] [Abstract][Full Text] [Related]
13. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.
Agarwal E; Chaudhuri A; Leiphrakpam PD; Haferbier KL; Brattain MG; Chowdhury S
BMC Cancer; 2014 Mar; 14():145. PubMed ID: 24581231
[TBL] [Abstract][Full Text] [Related]
14. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.
Dai D; Kumar NS; Wolf DM; Leslie KK
Am J Obstet Gynecol; 2001 Apr; 184(5):790-7. PubMed ID: 11303185
[TBL] [Abstract][Full Text] [Related]
15. MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition.
Burke JF; Schlosser L; Harrison AD; Kunnimalaiyaan M; Chen H
Ann Surg Oncol; 2013 Nov; 20(12):3862-8. PubMed ID: 23900743
[TBL] [Abstract][Full Text] [Related]
16. [Functional study of progesterone receptor isoforms in endometrial cancer cell lines].
Lu Y; Liao QP; Chen CL; Yu L
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):475-9. PubMed ID: 17068617
[TBL] [Abstract][Full Text] [Related]
17. AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.
Chen X; Cui D; Bi Y; Shu J; Xiong X; Zhao Y
Cell Cycle; 2018; 17(16):2069-2079. PubMed ID: 30198810
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of PDCD4 induced by progesterone is mediated by the PI3K/AKT signaling pathway in human endometrial cancer cells.
Wang X; Li Y; Wan L; Liu Y; Sun Y; Liu Y; Shi Y; Zhang L; Zhou H; Wang J; Wang X; Wei Z
Oncol Rep; 2019 Aug; 42(2):849-856. PubMed ID: 31233196
[TBL] [Abstract][Full Text] [Related]
19. Progestins activate the AKT pathway in leiomyoma cells and promote survival.
Hoekstra AV; Sefton EC; Berry E; Lu Z; Hardt J; Marsh E; Yin P; Clardy J; Chakravarti D; Bulun S; Kim JJ
J Clin Endocrinol Metab; 2009 May; 94(5):1768-74. PubMed ID: 19240153
[TBL] [Abstract][Full Text] [Related]
20. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.
Lin YH; Chen BY; Lai WT; Wu SF; Guh JH; Cheng AL; Hsu LC
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jan; 388(1):19-31. PubMed ID: 25164962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
